Editing Cystic fibrosis (section)

==== Antibiotic adjuvant therapy ====
Factors related to antibiotic use, the chronicity of the disease, and the emergence of resistant bacteria demand more exploration for different strategies such as antibiotic [[adjuvant]] therapy.<ref name="pmid32671834">{{cite journal | vauthors = Hurley MN, Smith S, Forrester DL, Smyth AR | title = Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis | journal = The Cochrane Database of Systematic Reviews | volume = 7 | issue = 7 | pages = CD008037 | date = July 2020 | pmid = 32671834 | pmc = 8407502 | doi = 10.1002/14651858.CD008037.pub4 }}</ref> Antibiotic adjuvant therapy refers to therapeutic approaches that aim to improve the action of antibiotics such a pharmaceutical agents or supplements that impact the virulence of the bacterium or that change the susceptibility of the organism to the antibiotic so that the antibiotics are more effective.<ref name="pmid32671834" /> There is no strong evidence to recommend specific antibiotic adjuvant therapies such as [[Β-Carotene|β-carotene]], [[nitric oxide]], [[zinc supplements]], or KB001-A.<ref name="pmid32671834" />